[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Myotonic Dystrophy Drug Market Report 2018

March 2018 | 97 pages | ID: U0A8EBD11C4QEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Myotonic Dystrophy Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Myotonic Dystrophy Drug in these regions, from 2013 to 2025 (forecast).
United States Myotonic Dystrophy Drug market competition by top manufacturers/players, with Myotonic Dystrophy Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • BioMarin Pharmaceutical Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Isis Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Valentia Biopharma S.L.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • ISIS-DMPKRx
  • PRO-135
  • SRT-152
  • VAL-0411
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Hospital
  • Clinic
  • Home Use
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Myotonic Dystrophy Drug Market Report 2018

1 MYOTONIC DYSTROPHY DRUG OVERVIEW

1.1 Product Overview and Scope of Myotonic Dystrophy Drug
1.2 Classification of Myotonic Dystrophy Drug by Product Category
  1.2.1 United States Myotonic Dystrophy Drug Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Myotonic Dystrophy Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 ISIS-DMPKRx
  1.2.4 PRO-135
  1.2.5 SRT-152
  1.2.6 VAL-0411
  1.2.7 Others
1.3 United States Myotonic Dystrophy Drug Market by Application/End Users
  1.3.1 United States Myotonic Dystrophy Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Home Use
  1.3.5 Others
1.4 United States Myotonic Dystrophy Drug Market by Region
  1.4.1 United States Myotonic Dystrophy Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Myotonic Dystrophy Drug Status and Prospect (2013-2025)
  1.4.3 Southwest Myotonic Dystrophy Drug Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Myotonic Dystrophy Drug Status and Prospect (2013-2025)
  1.4.5 New England Myotonic Dystrophy Drug Status and Prospect (2013-2025)
  1.4.6 The South Myotonic Dystrophy Drug Status and Prospect (2013-2025)
  1.4.7 The Midwest Myotonic Dystrophy Drug Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Myotonic Dystrophy Drug (2013-2025)
  1.5.1 United States Myotonic Dystrophy Drug Sales and Growth Rate (2013-2025)
  1.5.2 United States Myotonic Dystrophy Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES MYOTONIC DYSTROPHY DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Myotonic Dystrophy Drug Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Myotonic Dystrophy Drug Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Myotonic Dystrophy Drug Average Price by Players/Suppliers (2013-2018)
2.4 United States Myotonic Dystrophy Drug Market Competitive Situation and Trends
  2.4.1 United States Myotonic Dystrophy Drug Market Concentration Rate
  2.4.2 United States Myotonic Dystrophy Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Myotonic Dystrophy Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES MYOTONIC DYSTROPHY DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Myotonic Dystrophy Drug Sales and Market Share by Region (2013-2018)
3.2 United States Myotonic Dystrophy Drug Revenue and Market Share by Region (2013-2018)
3.3 United States Myotonic Dystrophy Drug Price by Region (2013-2018)

4 UNITED STATES MYOTONIC DYSTROPHY DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Myotonic Dystrophy Drug Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Myotonic Dystrophy Drug Revenue and Market Share by Type (2013-2018)
4.3 United States Myotonic Dystrophy Drug Price by Type (2013-2018)
4.4 United States Myotonic Dystrophy Drug Sales Growth Rate by Type (2013-2018)

5 UNITED STATES MYOTONIC DYSTROPHY DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Myotonic Dystrophy Drug Sales and Market Share by Application (2013-2018)
5.2 United States Myotonic Dystrophy Drug Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES MYOTONIC DYSTROPHY DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 BioMarin Pharmaceutical Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 F. Hoffmann-La Roche Ltd.
  6.2.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Genzyme Corporation
  6.3.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Genzyme Corporation Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Isis Pharmaceuticals, Inc.
  6.4.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Marina Biotech, Inc.
  6.5.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Marina Biotech, Inc. Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Valentia Biopharma S.L.
  6.6.2 Myotonic Dystrophy Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview

7 MYOTONIC DYSTROPHY DRUG MANUFACTURING COST ANALYSIS

7.1 Myotonic Dystrophy Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Myotonic Dystrophy Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Myotonic Dystrophy Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Myotonic Dystrophy Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES MYOTONIC DYSTROPHY DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Myotonic Dystrophy Drug Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Myotonic Dystrophy Drug Sales Volume Forecast by Type (2018-2025)
11.3 United States Myotonic Dystrophy Drug Sales Volume Forecast by Application (2018-2025)
11.4 United States Myotonic Dystrophy Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.


LIST OF TABLES AND FIGURES

Figure Product Picture of Myotonic Dystrophy Drug
Figure United States Myotonic Dystrophy Drug Market Size (K Pcs) by Type (2013-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure ISIS-DMPKRx Product Picture
Figure PRO-135 Product Picture
Figure SRT-152 Product Picture
Figure VAL-0411 Product Picture
Figure Others Product Picture
Figure United States Myotonic Dystrophy Drug Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Myotonic Dystrophy Drug by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Home Use Examples
Table Key Downstream Customer in Home Use
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Myotonic Dystrophy Drug Market Size (Million USD) by Region (2013-2025)
Figure The West Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Myotonic Dystrophy Drug Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Myotonic Dystrophy Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Myotonic Dystrophy Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Myotonic Dystrophy Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Myotonic Dystrophy Drug Sales Share by Players/Suppliers
Figure 2017 United States Myotonic Dystrophy Drug Sales Share by Players/Suppliers
Figure United States Myotonic Dystrophy Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Myotonic Dystrophy Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Myotonic Dystrophy Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Myotonic Dystrophy Drug Revenue Share by Players/Suppliers
Figure 2017 United States Myotonic Dystrophy Drug Revenue Share by Players/Suppliers
Table United States Market Myotonic Dystrophy Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Myotonic Dystrophy Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Myotonic Dystrophy Drug Market Share of Top 3 Players/Suppliers
Figure United States Myotonic Dystrophy Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Myotonic Dystrophy Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Myotonic Dystrophy Drug Product Category
Table United States Myotonic Dystrophy Drug Sales (K Pcs) by Region (2013-2018)
Table United States Myotonic Dystrophy Drug Sales Share by Region (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Share by Region (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Market Share by Region in 2017
Table United States Myotonic Dystrophy Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Myotonic Dystrophy Drug Revenue Share by Region (2013-2018)
Figure United States Myotonic Dystrophy Drug Revenue Market Share by Region (2013-2018)
Figure United States Myotonic Dystrophy Drug Revenue Market Share by Region in 2017
Table United States Myotonic Dystrophy Drug Price (USD/Pcs) by Region (2013-2018)
Table United States Myotonic Dystrophy Drug Sales (K Pcs) by Type (2013-2018)
Table United States Myotonic Dystrophy Drug Sales Share by Type (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Share by Type (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Market Share by Type in 2017
Table United States Myotonic Dystrophy Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Myotonic Dystrophy Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Myotonic Dystrophy Drug by Type (2013-2018)
Figure Revenue Market Share of Myotonic Dystrophy Drug by Type in 2017
Table United States Myotonic Dystrophy Drug Price (USD/Pcs) by Types (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Growth Rate by Type (2013-2018)
Table United States Myotonic Dystrophy Drug Sales (K Pcs) by Application (2013-2018)
Table United States Myotonic Dystrophy Drug Sales Market Share by Application (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Market Share by Application (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Market Share by Application in 2017
Table United States Myotonic Dystrophy Drug Sales Growth Rate by Application (2013-2018)
Figure United States Myotonic Dystrophy Drug Sales Growth Rate by Application (2013-2018)
Table BioMarin Pharmaceutical Inc. Basic Information List
Table BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table Genzyme Corporation Basic Information List
Table Genzyme Corporation Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Genzyme Corporation Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure Genzyme Corporation Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure Genzyme Corporation Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table Isis Pharmaceuticals, Inc. Basic Information List
Table Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table Marina Biotech, Inc. Basic Information List
Table Marina Biotech, Inc. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Marina Biotech, Inc. Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure Marina Biotech, Inc. Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure Marina Biotech, Inc. Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table Valentia Biopharma S.L. Basic Information List
Table Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales Growth Rate (2013-2018)
Figure Valentia Biopharma S.L. Myotonic Dystrophy Drug Sales Market Share in United States (2013-2018)
Figure Valentia Biopharma S.L. Myotonic Dystrophy Drug Revenue Market Share in United States (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Myotonic Dystrophy Drug
Figure Manufacturing Process Analysis of Myotonic Dystrophy Drug
Figure Myotonic Dystrophy Drug Industrial Chain Analysis
Table Raw Materials Sources of Myotonic Dystrophy Drug Major Players/Suppliers in 2017
Table Major Buyers of Myotonic Dystrophy Drug
Table Distributors/Traders List
Figure United States Myotonic Dystrophy Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Myotonic Dystrophy Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Myotonic Dystrophy Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Myotonic Dystrophy Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Myotonic Dystrophy Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Myotonic Dystrophy Drug Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories